NITI Aayog and ABB India Partner to Make India AI-Ready
The National Institution for Transforming India (NITI Aayog), the think tank of the Indian government, and ABB India have signed a Statement of Intent (SoI) to support the Indian government to realize its ambitious vision of “Make in India” through advanced manufacturing technologies that incorporate the latest developments in robotics and artificial intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523005618/en/
Anna Roy of NITI Aayog and Sanjeev Sharma, managing director of ABB India, sign a statement of partnership in advanced manufacturing technologies, including digital and AI, in New Delhi today. Looking on are Amitabh Kant, CEO of Niti Aayog, and Ulrich Spiesshofer, CEO of ABB (Photo: Business Wire)
NITI Aayog will work with ABB to prepare key sectors of the economy, such as the power and water utilities sector, industries like food as well as the heavy industries sector; and the transport (rail and metro) and infrastructure sectors for digitalization, the Internet of Things (IoT) and Artificial Intelligence (AI). The initiative also covers the fast growing segment of electric mobility. Jointly, NITI Aayog and ABB will work with government ministries, solicit feedback for areas critical to them and discuss solutions using industrial automation, and digitalization technologies.
“We are looking forward to learning more about practical applications of future technologies such as AI and IoT, especially in streamlining governance and economic systems. This collaboration, which will include cross-sectoral understanding of digitalization at ABB’s world class centers, will be key in driving progress of key sectors in India. This collaboration is meant to lead to actionable insights and focused plans that will help India become a center for advanced manufacturing,” said Amitabh Kant, CEO of NITI Aayog.
Through this SoI, NITI Aayog will facilitate policymakers and government functionaries’ participation in workshops and training programs organized by ABB India. Such programs will feature subject matter experts and will aim to sensitize policymakers and government officials about relevant AI capabilities, and explore ways they can be used for revolutionizing manufacturing productivity.
“We are excited to partner with NITI Aayog and develop ways for key areas of India’s economy to benefit from and implement the latest technologies in digitalization, artificial intelligence, robotics, and industrial automation. We look forward to working with key stakeholders in the Indian government, and supporting key initiatives of Prime Minister Modi such as ‘Make in India’,” said Dr. Ulrich Spiesshofer, CEO of ABB. “ABB’s more than a hundred years’ presence in India and our pioneering technology leadership in industrial digitalization position us well to support India in its ambitions for the next phase of its transformation.”
The first workshop for senior government officials, under this collaboration, would be organized in June, 2018, at the ABB Ability Innovation Center in Bengaluru. Given the importance of the Indian food processing sector, the workshop will focus on digital and automation technologies for this sector. Senior officials from the Central and State Governments as well as autonomous bodies will be nominated for this workshop. Similar workshops will be organized for other sectors such as power, urban development and transport in the near future.
NITI Aayog and all stakeholders will experience hands-on experience of ABB Ability™, the company’s comprehensive digital portfolio of solutions that deliver value of industrial digitalization to utilities, industries and transportation & infrastructure. ABB Ability™ integrates all of ABB’s services and domain expertise to turn data into analytic insights and direct action to drive competitiveness of Indian and global customers.
The workshops and training programs will be held at the ABB Ability Innovation Center (ABB AIC). As the company’s biggest research and development center in the world, located in Bengaluru, it develops technologies in areas such as AI, cyber security, automation engineering, data analytics, augmented and virtual reality and industrial software. ABB AIC also collaborates with premier academic institutes to pool expertise and funnel synergies for the benefit of society.
In addition, workshops will be held at ABB Power Technology Experience Center (ABB PowerTEC), Vadodara, India’s leading technology and knowledge training institute, which focuses on power engineering, grid automation and digitalization. Both facilities integrate best-in-class technologies and in-depth technical knowledge.
Based on the interactions with ABB India, NITI Aayog will also make recommendations to government ministries for guidelines and policies regarding development and adoption of AI technology in sectors such as power & water utilities, manufacturing, e-mobility and infrastructure, with industrial automation and digitalization as the backbone.
About NITI Aayog
The National Institution for Transforming India, also called NITI Aayog, was formed via a resolution of the Union Cabinet on January 1, 2015. NITI Aayog is the premier policy ‘Think Tank’ of the Government of India, providing both directional and policy inputs. While designing strategic and long term policies and programs for the Government of India, NITI Aayog also provides relevant technical advice to the Center and States. As part of a larger mandate to promote scientific endeavor and evolve a National AI Policy, NITI Aayog is establishing a series of partnerships with industry pioneers to promote indigenous advanced manufacturing, build capacity in frontier technologies and promote the ‘Make in India’ initiative of the Government of India.
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing a history of innovation spanning more than 130 years, ABB today is writing the future of industrial digitalization with two clear value propositions: bringing electricity from any power plant to any plug and automating industries from natural resources to finished products. As title partner of Formula E, the fully electric international FIA motorsport class, ABB is pushing the boundaries of e-mobility to contribute to a sustainable future. ABB operates in more than 100 countries with about 135,000 employees. www.abb.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180523005618/en/
Contact information
ABB Ltd
Media Relations
Phone: +41 43 317 71 11
Email:
media.relations@ch.abb.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom